Clinical Nuclear Medicine · 2015 · 19 citations · 6 references
MedicineNuclear MedicineOncologyDiagnostic ImagingDiagnostic RadiologyOncologic ImagingLymph Node PathologyLymphoma ImagingPositron Emission TomographyTumor Detection18F-fluorodeoxyglucose ImagingDisease Progression VisualizationMonoclonal Antibody InfusionNon-hodgkin Lymphoma ImagingNon-hodgkin Lymphoma TherapyNon-hodgkin Lymphoma TreatmentReactive Lymphoid LesionsRituximab-based Therapy
We report the case of a 45-year-old woman diagnosed with non-Hodgkin lymphoma. Six months after completion of R-CHOP, she relapsed, and 2 cycles of R-ESHAP were given, with a view to allograft transplant. One month later, F-FDG PET/CT revealed disease progression. Biopsy of lymph nodes showed reactive changes, without evidence of lymphoma. Rituximab, a monoclonal antibody, is used for treatment of non-Hodgkin lymphoma, but its addition may result in an extensive inflammatory response. It is important to be aware of the potential for false-positive F-FDG PET/CT imaging after rituximab therapy. Unexpected findings should be confirmed by biopsy.
6
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text
Life Sciences, Immunology, Pathology +14